-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Evolus (EOLS)
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Evolus (EOLS)
-
-
-
-
-
-
-
Study finds Evolus Jeuveau shows fast onset among four neurotoxins
-
-
-
-
-
-
-
BTIG Starts Evolus (EOLS) at Buy
-
-
-
-
-
-
-
Evolus (EOLS) Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue
-
-
-
-
-
-
-
Evolus (EOLS) Misses Q2 EPS by 13c ; Offers Guidance
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

